Immunizing Agent
Influenza A (H1N1) 2009
INJECTABLE inactivated Vaccines

Introduction

Inactivated influenza A (H1N1) 2009 vaccines are manufactured by Sanofi Pasteur, Novartis, GlaxoSmithKline and CSL Biotherapies. The age groups for which specific inactivated influenza A (H1N1) 2009 vaccines are recommended vary with manufacturer and vaccine presentation. These vaccines are recommended for use in persons 6 months old and older.

On August 28, 2009, the Advisory Committee on Immunization Practices (ACIP) recommended the use of influenza A (H1N1) 2009 vaccines for the following target groups (not listed in order of priority):

- pregnant women,
- persons who live with or provide care for infants aged less than 6 months (*e.g.*, parents, siblings, and daycare providers),
- health-care and emergency medical services personnel,
- children and young adults aged 6 months through 24 years and
- persons aged 25 through 64 years who have medical conditions that put them at higher risk for influenza-related complications.

Note: Pending availability of vaccine, these groups may be modified per Wisconsin Division of Public Health directives.

Schedule

- Children 6 months through 9 years of age: Two doses separated by at least 21 days. The optimal interval is 28 days.
- Persons 10 years and older: One dose.

Contraindications

- Acute illness, or oral (or equivalent) temperature elevation $\geq$ 100.4º F (38 º C).
- History of a serious allergic reaction to eggs or to a previous dose of influenza vaccine.

Precautions

- Persons with a history of Guillian-Barré syndrome (GBS) should not receive the vaccine.

Reactions

- Pain, redness and or swelling at the injection site and mild fever.

Cleansing Agent

- Alcohol to injection site.

Site of Administration

- Intramuscular into the anterolateral aspect of the upper thigh for young children or
- in the deltoid for older children and adults

Dosage

- For children 6 months through 35 months (2 years) of age administer 0.25 mL.
- For persons 3 years of age or older administer 0.5 mL.

Manufacturer	Presentation	Age group	Number of doses
Sanofi Pasteur	0.25 mL prefilled syringe	6 mos. through 2 years	2
	0.5 mL prefilled syringe	3 years and older	1 or 2
	5.0 mL multidose vial	6 months and older	1 or 2
Novartis	0.5 mL prefilled syringe	4 years and older	1 or 2
	5.0 mL multidose vial	4 years and older	1 or 2
GlaxoSmithKline*	0.5 mL multidose vial	18 years and older	1
CSL Biotherapies	0.5 mL prefilled syringe	3 years and older	1 or 2
	5.0 mL multidose vial	6 months and older	1 or 2

** anticipated to be available in December 2009.*

Simultaneous administration of seasonal and Influenza A (H1N1) 2009 vaccines

In an individual who will be vaccinated with both seasonal (trivalent) vaccine and H1N1 2009 (monovalent) vaccines:

- If both vaccines are inactivated they may be received during the same visit at different anatomical sites or they may be received on different dates at any time.
- If one vaccine is inactivated and one vaccine is live attenuated, they may be received during the same visit or they may be received on different dates at any time.
- If both vaccines are live attenuated, they should not be received during the same visit but can be received if separated by a minimum of 4 weeks.

Two doses of (H1N1) 2009 vaccines from different vaccine manufacturers

- If a child needs two doses of (H1N1) 2009 vaccine it is preferable to receive the same type of vaccine for both doses from the same manufacturer .
- It is permissible to receive two doses of inactivated (H1N1) 2009 vaccine from different manufacturers as long as the correct vaccine presentations are administered to the correct age groups separated by at least by 21-28 days.
- It is permissible to receive an inactivated (H1N1) 2009 vaccine as the first dose and a live (H1N1) 2009 vaccine as the second dose or vice versa separated by at least 21-28 days.

Simultaneous administration of (H1N1) 2009 vaccine and other childhood vaccines

- Inactivated (H1N1) 2009 vaccine can be administered at the same visit as any other vaccine (*e.g.*, DTaP, MMR).

- Live attenuated (H1N1) 2009 vaccine can be administered at the same visit as any other live or inactivated vaccine EXCEPT seasonal (trivalent) live attenuated influenza vaccine. If a live virus vaccine (*e.g.* varicella) is needed subsequent to receipt of (H1N1) 2009 vaccine a minimum interval of 28 days is recommended.

Storage

Refrigerate at 35 ^{o} - 46 ^{o} F (2 ^{o} -8 ^{o} C). Do not freeze. Doses drawn up into syringes before a clinic but not used by the end of the clinic should be discarded, not saved for another day's clinic.

(Rev 11/18 /09)